Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005001 · ClinicalTrials.gov registry record · Phase 2
Safety and Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)
A Phase 2 study, sponsored by Agouron Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00005001 is a Phase 2 study that has completed, run by Agouron Pharmaceuticals. The registered enrollment target is 40 participants.
The verdict
NCT00005001, a Phase 2 study, has completed, sponsored by Agouron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to see if giving HIV-positive patients an HIV vaccine plus anti-HIV drugs can help lower HIV levels in the blood (viral load).
Interventions
- BIOLOGICAL HIV-1 Immunogen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005001
The ClinicalTrials.gov registry entry for NCT00005001 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Agouron Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HIV-1 Immunogen is the first listed.
NCT00005001 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005001 about?
NCT00005001 is a clinical study titled "Safety and Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)". The purpose of this study is to see if giving HIV-positive patients an HIV vaccine plus anti-HIV drugs can help lower HIV levels in the blood (viral load).
What is the current status of trial NCT00005001?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants.
What interventions are being tested in trial NCT00005001?
The interventions under investigation include: HIV-1 Immunogen (BIOLOGICAL).
Who is sponsoring clinical trial NCT00005001?
This trial is sponsored by Agouron Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.